SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SU Group Holdings Ltd. engages in the provision of security-related engineering services, and security guarding and screening services. It operates through the Security-Related Engineering Services and Security Guarding and Screening Services segments. The company was founded by Ming Chan in 1998 and is headquartered in Hong Kong.

SU Group Holdings Ltd. - Ordinary Shares - Class A

SU Group Holdings Ltd.

SUGP is trending due to its regained NASDAQ compliance and a recently announced, record-breaking contract, leading to speculation about a potential short squeeze. Traders are drawing comparisons to other Hong Kong-based stocks that have experienced significant gains, fueled by its low float and high cost to borrow. The community is actively monitoring the stock for a potential breakout.

Pepek Philippe is a whimsical meme coin inspired by the lavish lifestyle of billionaire frogs flaunting luxury watches. This project humorously showcases the world of amphibious elites who enjoy opulence, fine dining, private jets, beautiful women, fast cars, mansions, and, of course, top-tier timepieces. The coin celebrates this absurdly rich lifestyle, blending humor with luxury culture to create a fun, engaging crypto experience.

Pepek Philippe

Pepek Philippe ($PEPEK) is trending as community members highlight recent coin burns and encourage others to load up, anticipating a significant surge. Many are pointing to the ease of access via Phantom Wallet as a catalyst, while others express strong conviction, emphasizing "diamond hands" and potential for substantial returns. The coin is generating excitement as a potential early gem within the meme coin space.

Terra 2.0 which will assume the Terra name is a new blockchain launched by Terraform Labs as part of the passing of governance proposal 1623.  The Terra protocol is a decentralized and open-source public blockchain protocol. Luna is the Terra protocol’s native staking token used for governance and mining.  Users stake Luna to validators who record and verify transactions on the blockchain in exchange for rewards from transaction fees.  The Terra 2.0 chain will not have a stablecoin and holders of the old Terra Classic chain will be airdropped new Luna native coins. In the plan, developers of the Terra ecosystem are to migrate and deploy their dapps on the new blockchain.

Terra 2.0

LUNA is trending amid discussions about its potential, with some viewing it as a promising project with a limited supply, while others are focused on a $7.3M settlement for investors who claim they were misled. The community is also closely watching developments within the Terra ecosystem and the implications of Do Kwon's legal situation.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

$RAGE is trending as the community rallies around the memecoin, referencing its origins as an OG meme from 2008. The community is expressing bullish sentiment and encouraging others to join, emphasizing community and expressing excitement. Social media raids and spaces are a key component of the community.

Melania memes are digital collectibles intended to function as an expression of support for and engagement with the values embodied by the symbol MELANIA

Melania Trump

MELANIA CRYPTO is trending amidst community discussions about potential scams and significant losses for investors in Trump-related memecoins. Community members are debating the coin's current and future value, with some labeling it a 'scam' and others speculating on potential pumps, influenced by the broader performance of other Trump-related assets. The coin's volatility and association with the Trump family continue to fuel discussions.

Terra is a decentralized financial payment network that rebuilds the traditional payment stack on the blockchain. Luna is the reserve currency of the Terra platform. It has three core functions: i) mine Terra transactions through staking, ii) ensure the price stability of Terra stablecoins and iii) provide incentives for the platform’s blockchain validators.

Terra Luna Classic

Terra Luna Classic ($LUNC) is trending amidst discussions around its deflationary USD, DUSD, and potential for future growth due to token burning mechanisms. The community is actively speculating on potential price movements and the possibility of a crypto bull run, while also highlighting projects that aim to revive LUNC. Sentiment is mixed, with some expressing long-term hope and others remaining skeptical about its recovery.

Ethena

Ethena (ENA) is trending due to increased attention on its USDe stablecoin, amplified by news of a substantial capital raise for StablecoinX, a company focused on building an Ethena treasury. The community is discussing ENA's potential growth, driven by its integration with traditional finance and innovative approach to stablecoins, while some express concerns about volatility.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is trending as community members express excitement and promote its vision, with some drawing comparisons to Bitcoin. Discussions center around the coin's potential to revolutionize the cannabis market and its connection to the broader cannabis culture. The community emphasizes its mission to challenge traditional pharmaceutical approaches and promote natural medicine.

Bank Of Nova Scotia

Bank of Nova Scotia is trending as investors digest the implications of Q3 2025 earnings, which exceeded EPS expectations but also factored in workforce reductions as part of a cost-cutting strategy. The community is weighing analyst opinions, including Canaccord Genuity's maintained Buy rating, against the backdrop of economic trends in Colombia and concerns about potential market corrections. Discussions also involve Scotiabank's strategic moves in Guyana and its bond program, within the context of the broader Canadian banking sector's performance and discussions of defensive stock picks for bear markets.

Aptos is a new, independent high-performance PoS Layer 1 project focused on delivering the safest and most scalable Layer 1 blockchain in the world. The Aptos blockchain leverages the Move programming language and the Move VM for application development, which are created and optimized for blockchain use cases.The team is comprised of the original creators, researchers, designers, and builders of Diem, the blockchain that was first built to serve this purpose. Aptos raised $200m from a16z, Multicoin, Binance and others. Aptos launched Devnet in mid March, incentivized testnet in late May and targets Q3 for mainnet launch.

Aptos

Aptos is trending as traders discuss potential shorting opportunities, citing a break below a key support level. Community members are pointing to increased stablecoin supply on Aptos and the upcoming launch of a Trump-affiliated stablecoin as possible catalysts. Some users are also comparing Aptos to other Layer 1 blockchains like Solana and Ethereum, while others are evaluating potential competitors like Keeta.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

What Makes Spruce Biosciences, Inc. (SPRB) a Strong Momentum Stock: Buy Now?

Does Spruce Biosciences, Inc. (SPRB) have what it takes to be a top stock pick for momentum investors? Let's find out.

Shares of Spruce Biosciences (SPRB) surged to a 19-month high of $240 in Tuesday morning trading, prompting two trading halts due to extreme volatility.Trading was halted at 9:32 a.m. ET and again at 9:48 a.m. ET, according to data from Nasdaq Trader, citing a ‘Volatility Trading Pause’.<a href="http://stocktwits.com/symbol/SPRB">SPRB’s stock</a> was up 74%, trading around $229 at the time of writing. It ranked among the top trending tickers on Stocktwits, with retail sentiment climbing higher within ‘extremely bullish’ territory amid ‘extremely high’ chatter – recording the highest levels of retail activity seen this year. Data also showed that the number of retail traders monitoring SPRB shares jumped 76% over the past day.<figure class="image"><img style="aspect-ratio:1259/133;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_07_101031_png_dc3a1a3a6c.webp" alt="Screenshot 2025-10-07 101031.png" width="1259" height="133"><figcaption>SPRB retail sentiment and message volume on October 7 as of 10:00 a.m. ET | Source: Stocktwits</figcaption></figure>The rally follows Spruce Biosciences’ shares jumping 1,378% to close at $130.4 on Monday after the U.S. Food and Drug Administration (FDA)&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/spruce-biosciences-stock-more-than-quadruples-after-breakthrough-therapy-designation-to-therapy-for-rare-fatal-genetic-disease/ch6R7WfR3gl">granted</a> Breakthrough Therapy Designation to tralesinidase alfa enzyme replacement therapy (TA-ERT) for the treatment of Sanfilippo Syndrome Type B (MPS IIIB).Martin Shkreli also&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/spruce-biosciences-stock-nearly-doubles-premarket-pharma-bro-martin-shkreli-sees-280-upside/ch6PEVhR3Wj">disclosed</a> his long position in Spruce and expressed a bullish outlook. In a&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/MartinShkreli/status/1975241784369262649">post</a> on X, Shkreli said he believes the treatment “will be approved” and become “the new standard of care,” predicting that Spruce’s stock could rise to $500. Shkreli, a former hedge fund manager and pharmaceutical executive who&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.justice.gov/usao-edny/pr/martin-shkreli-sentenced-seven-years-imprisonment-multi-million-dollar-fraud-scheme">served time</a> for securities fraud, did not provide a timeline for the forecast.MPS IIIB is a rare, inherited lysosomal storage disease that causes a gradual decline in motor skills and cognition, as well as hyperactivity with aggressive behavior. CEO Javier Szwarcberg said on Monday that the company is preparing to submit an application for approval of the therapy in MPS IIIB in the first quarter of 2026.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/cryptocurrency/bnb-token-surges-to-record-high-overtakes-xrp-as-third-largest-cryptocurrency/ch6PaXTR3Wy">BNB Token Surges To Record High, Overtakes XRP As Third-Largest Cryptocurrency</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representative image of abstract numbers amid rising stock market prices. (Photo by SEAN GLADWELL/Getty Images)

SPRB Stock Hits 19-Month High Amid Trading Halts

The rally follows Spruce Biosciences’ shares jumping 1,378% to close at $130.4 on Monday.

Equity

The rally follows Spruce Biosciences’ shares jumping 1,378% to close at $130.4 on Monday.


Spruce Biosciences' stock&nbsp;leaped over 90% in early premarket trading on Tuesday, topping the Stocktwits trending list,&nbsp;hours after investor Martin Shkreli disclosed his long position on the stock and discussed his optimistic outlook.That's after SPRB stock gained a staggering 1,378% to $130.4 in Monday's session, following the company's announcement that it&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/spruce-biosciences-stock-more-than-quadruples-after-breakthrough-therapy-designation-to-therapy-for-rare-fatal-genetic-disease/ch6R7WfR3gl">received</a> the FDA's 'Breakthrough Therapy Designation' for its new therapy for a rare neurological disease.Spruce's tralesinidase alfa enzyme replacement therapy (TA-ERT) is designed to treat Sanfilippo syndrome type B (MPS IIIB), a rare, inherited lysosomal storage disease that causes a gradual decline in motor skills and cognition, as well as hyperactivity with aggressive behavior.Shkreli said in an&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/MartinShkreli/status/1975241784369262649">X post</a> early Tuesday he believes the said treatment "will be approved" and become "the new standard of care," forecasting that it would push Spruce's stock to $500.&nbsp;Shkreli, a former hedge fund manager and pharmaceutical executive who has served time in jail for securities fraud, did not provide a timeline."I was working on a presentation when the news was scooped. but this drug restores the abnormally high levels of heparan sulfate to normal. without this drug, patients will die at 18. with normal ranges of HS, they may live a normal life," he said in a follow-up post.CEO Javier Szwarcberg&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.businesswire.com/news/home/20251006024469/en/Spruce-Biosciences-Receives-U.S.-FDA-Breakthrough-Therapy-Designation-for-Tralesinidase-Alfa-Enzyme-Replacement-Therapy-TA-ERT-in-Sanfilippo-Syndrome-Type-B-MPS-IIIB">said</a> on Monday that the company is preparing to submit an application for approval of the therapy in MPS IIIB in the first quarter of 2026. According to Spruce, Sanfilippo Syndrome Type B affects one in 200,000 people in the U.S.FDA's 'Breakthrough Therapy Designation' expedites the development and regulatory review of promising therapies for serious or life-threatening conditions, with intensive FDA guidance.Notably, Shkreli also recently&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/pharma-bro-martin-shkreli-bets-against-opendoor-but-retail-traders-call-it-an-obvious-long-backed-by-eric-jackson/chw0M0bRdsE">revealed a short position</a> in Opendoor Technologies' shares, a widely watched meme stock.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Spruce Biosciences Stock Nearly Doubles Premarket: 'Pharma Bro' Martin Shkreli Sees 280% Upside

SPRB stock surged by over 1,300% on Monday after the biotech firm received the FDA's 'Breakthrough Therapy Designation' for its new therapy for a rare neurological disease.

Spruce Biosciences (SPRB) on Monday said that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to tralesinidase alfa enzyme replacement therapy (TA-ERT) for the treatment of Sanfilippo Syndrome Type B.Sanfilippo syndrome type B (MPS IIIB) is a rare, inherited lysosomal storage disease caused by a deficiency in the enzyme alpha-N-acetylglucosaminidase, leading to the accumulation of heparan sulfate in cells, particularly neurons. It causes progressive neurological symptoms like cognitive and developmental impairment, hyperactivity with aggressive and destructive behavior, delayed speech, hearing loss, and motor skill deficits.Tralesinidase Alfa Enzyme Replacement Therapy is intended as an enzyme replacement therapy for the treatment of patients with MPS IIIB. The Breakthrough Therapy Designation is designed to expedite the development and regulatory review of promising therapies for serious or life-threatening conditions. It enables intensive FDA guidance and eligibility for rolling submission and priority review.Shares of SPRB traded 314% higher at the time of writing on Monday. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/SPRB">SPRB stock</a> jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours while message volume stayed at ‘extremely high’ levels.CEO Javier Szwarcberg <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.businesswire.com/news/home/20251006024469/en/Spruce-Biosciences-Receives-U.S.-FDA-Breakthrough-Therapy-Designation-for-Tralesinidase-Alfa-Enzyme-Replacement-Therapy-TA-ERT-in-Sanfilippo-Syndrome-Type-B-MPS-IIIB">said</a> that the company is preparing to submit an application for approval of the therapy in MPS IIIB in the first quarter of 2026. According to Spruce, Sanfilippo Syndrome Type B affects one in 200,000 people in the U.S.Currently, there are no FDA-approved therapies for the disease, which drastically brings down the life expectancy of individuals to 15-19 years of age.SPRB stock rose over 200% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/us-listed-nyxoah-shares-soar-on-first-genio-system-implants-in-patients-with-sleep-disorder/ch6R4LYR3g1">US-Listed Nyxoah Shares Soar On First Genio System Implants In Patients With Sleep Disorder</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Why Did Spruce Biosciences Stock Quadruple Today?

The FDA’s Breakthrough Therapy Designation is designed to expedite the development and regulatory review of promising therapies for serious or life-threatening conditions.

Puma Biotech (PBYI) Surpasses Q2 Earnings and Revenue Estimates

Puma Biotech (PBYI) delivered earnings and revenue surprises of +36.36% and +4.42%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Curis (CRIS) Reports Q2 Loss, Beats Revenue Estimates

Curis (CRIS) delivered earnings and revenue surprises of +65.83% and +14.54%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Illumina (ILMN) Q2 Earnings and Revenues Surpass Estimates

Illumina (ILMN) delivered earnings and revenue surprises of +16.67% and +1.11%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Spruce Biosciences Announces Topline Results from CAHmelia-204 in Adult CAH and CAHptain-205 in Adult and Pediatric CAH

Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological and endocrine disorders with significant...

Spruce Biosciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and neurological disorders with significant...

Spruce Biosciences to Participate in the Guggenheim Securities Healthcare Innovation Conference

Spruce Biosciences, Inc. is a biopharmaceutical company, which engages in developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need. The company was founded on November 13, 2014 and is headquartered in South San Francisco, CA.

Spruce Biosciences Inc

Will Netflix ($NFLX) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Netflix Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

SPRB
Spruce Biosciences Inc

Feed

News

Sentiment

Fundamentals

Info

Latest SPRB News

SPRBSpruce Biosciences Inc